Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experimental squalene adjuvant. II. Harmlessness and local reactogenity.

Zdenek Benísek1, Judit Süli, Daniel Eliás

  • 1Department of Infectious and Parasitic Diseases, University of Veterinary Medicine, Kosice, Slovak Republic.

Vaccine
|August 17, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Record of <i>Ixodes ariadnae</i> (Acari: Ixodidae) in Slovakia.

Animals : an open access journal from MDPI·2026
Same author

Catechin Augments the Antifungal Efficacy of Fluconazole Against <i>Candida parapsilosis</i>.

International journal of molecular sciences·2026
Same author

Sedation, Sleep, and Sudden Death: How ICU Sedation Alters Cardiac Rhythmicity and Autonomic Tone.

Cardiology in review·2026
Same author

Serological evidence of <i>Anaplasma</i> spp. antibodies in domestic ruminants in Slovakia.

Annals of agricultural and environmental medicine : AAEM·2025
Same author

Electromechanical Uncoupling in Critical Illness: Arrhythmia Mechanisms During ECMO and Ventricular Assist Device Support.

Cardiology in review·2025
Same author

Influence of Methomyl and Salinity on the Freshwater Snail <i>Physa venustula</i>: Egestion, Movement, and Hydration Index.

Tropical life sciences research·2025
Same journal

Adverse events and vaccine administration errors following RSV vaccination: Findings from the United States VAERS database, 2023-2025.

Vaccine·2026
Same journal

Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies.

Vaccine·2026
Same journal

Human systemic and mucosal immune responses support further exploration of a Klebsiella pneumoniae protein-based vaccine.

Vaccine·2026
Same journal

Corrigendum to "Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial" [Vaccine 42(9) (2024) 2254-2259].

Vaccine·2026
Same journal

Innovative webinar-based training to support evidence-to-recommendation decision-making by national immunization technical advisory groups: multi-country experience with hexavalent vaccines.

Vaccine·2026
Same journal

Under-vaccination as a systems failure: A Monte Carlo simulation of the 2025 CDC/ACIP hepatitis B birth-dose policy shift and multi-level intervention packages, 2025-2035.

Vaccine·2026
See all related articles

This study found that the experimental squalene adjuvant (ESA) did not cause allergic reactions or significant local tissue reactions in guinea pigs. Pyrogenicity tests also confirmed ESA

Area of Science:

  • Immunology
  • Toxicology
  • Adjuvant Research

Background:

  • Adjuvants are crucial for enhancing immune responses.
  • Squalene-based adjuvants are being explored for their potential.
  • Assessing the safety and reactivity of new adjuvants is essential.

Purpose of the Study:

  • To evaluate the allergenic potential and sensitization capacity of an experimental squalene adjuvant (ESA).
  • To assess the local tissue reactivity and reactogenicity of ESA following repeated administration.
  • To confirm the pyrogenicity and overall safety profile of ESA.

Main Methods:

  • Guinea pigs were subjected to repeated administration of ESA.
  • Sensitization and provocation tests were performed.
  • Comparative patho-anatomical and patho-histological examinations were conducted at the administration site.

Related Experiment Videos

  • Pyrogenicity testing was performed using labeled lysate sensitivity.

    • Main Results:

    • No significant allergic reactions or sensitization were observed in animals treated with ESA compared to controls.
    • Examinations revealed very low local tissue reactivity and reactogenicity associated with ESA administration.
    • Pyrogenicity tests confirmed ESA's safety, with labeled lysate sensitivity below 0.25 IU/cm3.

    Conclusions:

    • The experimental squalene adjuvant (ESA) demonstrates a favorable safety profile.
    • ESA exhibits minimal allergenic potential and low local tissue reactivity.
    • ESA is a safe and potentially effective lipoid adjuvant for further research and development.